Scientific Issues for Biogenerics/Biosimilars

Abstract

Recent changes in perspective at the US Food and Drug Administration and in the EU have clearly indicated a commitment to an abbreviated development and regulatory pathway for follow-on biological drugs (or biogenerics). This process has been discussed only in fairly abstract terms, however, and definitions and concrete requirements that could guide manufacturers of these products with regard to data requirements for an abbreviated submission are still needed. The aim of this paper is to summarise some of the critical scientific issues that will have an impact on the development of programmes for biogenerics. This paper discusses in some detail the likely necessity for developers of biogenerics to chemically and structurally characterise both their own follow-on product as well as the innovator's product in order to demonstrate a sufficient level of biosimilarity. Issues related to the characterisation of a biogeneric's biological activity are discussed, as are issues related to toxicity risks. It is the authors' belief that the term ‘biosimilar’, as opposed to the high level of required structural identity between a generic chemical drug and its innovative product, best describes the nature of follow-on biologics that would qualify for expedited development. Interpreting the clinical importance of demonstrated dissimilarities between innovator and biosimilar products is likely to be the greatest challenge for manufacturers of biogenerics, with requirements for human clinical testing being decided by regulatory agencies on a case by case basis.

Keywords

biogenerics biosimilar medical products follow-on biologics abbreviated development generic biologics

Get full access to this article

View all access options for this article.

References

Anon (2004) ‘FDA generic biologics “structure” to come soon: Policy debate in 2005’, The Pink Sheet, 5th April, pp. 7–8.

Anon (2004) ‘FDA “follow-on” biologics guidance: A preview’, The Pink Sheet, 10th May, pp. 4–5.

Commission Directive 2003/63/EC of 25th June, 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official Journal of the European Union L 159/46.

Draft Guidance ICH Q5E: Comparability of biotechnology/biological products subject to their manufacturing process. Available at: http://www.fda.gov/cder/guidance/6003dft.pdf .

Anon (1999) ‘FDA procedure for some generic biologics?’, SCRIP No. 2428, p. 15.

Cumming

D. A.

(1991) ‘Glycosylation of recombinant protein therapeutics: Control and functional implications’, Glycobiology, Vol. 1, pp. 115–130.

Takeuchi

Inoue

Strickland

T. W.

(1989) ‘Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells’, Proceedings of the National Academy of Science USA, Vol. 86, pp. 7819–7822.

Boddy

A. W.

Snikeris

F. C.

Kringle

R. O.

(1995) ‘An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs’, Pharmaceutical Research, Vol. 12, pp. 1865–1868.